A potential drug-herbal interaction between Ginkgo biloba and efavirenz

Journal of the International Association of Physicians in AIDS Care

Volumn 11, Issue 2, 2012, Pages 98-100

  Naccarato, Mark ^a   Yoong, Deborah ^a   Gough, Kevin ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

antiretroviral; drug interaction; efavirenz; Ginkgo biloba; HIV

Indexed keywords

CALCIUM; EFAVIRENZ; GINKGO BILOBA EXTRACT; MAGNESIUM; OMEGA 3 FATTY ACID; RUTOSIDE; VITAMIN D;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CHESTNUT; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; GENOTYPE; HERB DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GINKGO BILOBA; HIV SEROPOSITIVITY; HUMANS; LAMIVUDINE; MALE; PLANT EXTRACTS; VIRAL LOAD; ZIDOVUDINE;

EID: 84859301201     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109711435364     Document Type: Article

References (21)

1. Eshleman S, Hackett J, Swanson P, Cunningham S, Drews B, Brennan C. Performance of Celera Diagnostics ViroSeq HIV-1 genotyping system for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Micro. 2004;42(6): 2711-2717. (Pubitemid 38747526)
2. Wiegman D, Brinkman K, Franssen E. Interaction of Ginkgo biloba with efavirenz. AIDS. 2009;23(9):1181-1185.
3. Ward B, Gorski C, Jones D, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306(1):287-300. (Pubitemid 36734384)
4. Ogburn E, Jones D, Masters A, Xu C, Guo Y, Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos. 2010;38(7):1218-1229.
5. Lau AJ, Yang G, Rajaraman G, Baucom CC, Chang TK. Human pregnane X receptor agonism by Ginkgo biloba extract: assessment of the role of individual ginkgolides. J Pharmacol Exp Ther. 2010;335(3):771-780.
6. Deng Y, Bi HC, Zhao LZ, et al. Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica. 2008;38(5):465-481. (Pubitemid 351550976)
7. Taki Y, Yamakazi Y, Shimura F, Yamada S, Umegaki K. Time-dependent induction of hepatic cytochrome P450 enzyme activity and mRNA expression by bilobalide in rats. J Pharmacol Sci. 2009;109(3):459-462.
8. Uchida S, Yamada H, Li XD, et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol. 2006;46(11):1290-1298. (Pubitemid 44564357)
9. Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol. 2003;23(6):576-581. (Pubitemid 37443189)
10. Robertson S, Davey R, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Cur Med Res and Opin. 2008;24(2):591-599. (Pubitemid 351294409)
11. Lau A, Chang T. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by ginkgo biloba extract: effect of terpene trilactones and flavonols. Drug Metab Dispos. 2009;37(9): 1931-1937.
12. Lei HP, Ji W, Lin J, et al. Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol. 2009;68(2):201-206.
13. Woelkart K, Feizlmayr E, Dittrich P, et al. Pharmacokinetics of Bilobalide, Ginkgolide A and B after administration of three different Ginkgo biloba L. Preparations in humans. Phytother Res. 2010;24(3):445-450.
14. Di Mascio M, Markowitz M, Louie M, et al. Viral blip dynamics during highly active antiretroviral therapy. J Virol. 2003;77(22): 12165-12172. (Pubitemid 37339869)
15. Nettles R, Kieffer T, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005;293(7):817-829. (Pubitemid 40250365)
16. Podsadecki T, Vrijens B, Tousset E, Rode RA, Hanna GJ. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Diseas. 2007;196(12):1773-1778. (Pubitemid 351411937)
17. Horn JR, Hansten P, Chan LT. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4): 674-680. (Pubitemid 46625492)
18. Hellum B, Nilsen O. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Bas Clin Pharmacol Toxicol. 2008;102(5):466-475. (Pubitemid 351537792)
19. Hellum B, Hu Z, Nilsen O. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Bas Clin Pharmacol Toxicol. 2007;100(1): 23-30. (Pubitemid 46051439)
20. Hellum B, Hu Z, Nilsen O. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Bas Clin Pharmacol Toxicol. 2009;105(1):58-63.
21. Abad MJ, Bedoya LM, Bermejo P. An update on drug interactions with the herbal medicine Ginkgo biloba. Curr Drug Metab. 2010; 11(2):171-181.